Colossal Biosciences has successfully raised $200 million in a Series C funding round, achieving a remarkable $10.2 billion valuation. This funding was led by TWG Global, with participation from notable investors like Mark Walter and Thomas Tull. The company aims to resurrect woolly mammoths, Tasmanian tigers, and dodo birds using advanced gene-editing technologies. Co-founder Ben Lamm highlighted the impressive technological advancements made since their last funding round. Colossal also plans to develop artificial wombs and collaborate with governments on conservation efforts, anticipating significant revenue from biodiversity credits.